PAREA launches new policy brief calling for the European Biotech Act to deliver on mental health innovation

At an event today at the European Parliament in Brussels, PAREA launched its new policy brief, Mental Health Innovation in the European Biotech Act: Closing Europe’s access and competitiveness gap, calling on EU policymakers to secure mental health’s place in the final Act and strengthen support for bringing new treatments to patients.

The event, Mental health innovation in the European Biotech Act: closing Europe’s access and competitiveness gap, was hosted by MEP Romana Jerković and organised by PAREA, GAMIAN-Europe and the European College of Neuropsychopharmacology. It brought together patient representatives, policymakers and experts to discuss how Europe can close the gap between scientific advances and accessible care.

The brief highlights the scale of Europe’s psychiatric innovation gap. Citing ECNP’s analysis, it reports that between 2016 and 2025, the US approved 38 new psychiatric medicines across seven indications, compared with 11 in Europe. Fragmented reimbursement, uncertainty over evidence requirements and weak commercial incentives continue to discourage investment and delay access.

The proposed European Biotech Act offers an opportunity to address these barriers. While the Commission’s proposal contains no explicit reference to mental health, Parliament’s draft compromise introduces recognition across strategic mapping, foresight, developer support, cross-border networks and regulatory sandboxes.

PAREA calls for these provisions to be preserved in the final legislation and for Member States to build on them with practical support for public-led development and repurposing.

PAREA’s four priorities for the final Act

  • Direct innovation towards unmet mental health needs. Use strategic mapping and foresight to identify gaps in development and access, with people with lived and living experience helping define priorities and meaningful outcomes.

  • Build Europe’s capacity to develop mental health treatments. Connect clinical networks, regulatory advice and shared evidence collection to support approval, reimbursement and safe delivery.

  • Attract investment into mental health innovation. Direct the Act’s investment tools towards eligible programmes held back by insufficient funding, with transparent results, patient involvement and credible plans for access.

  • Back public-led development and repurposing. Support public and nonprofit developers with funding for clinical studies, evidence generation and regulatory work where commercial incentives are insufficient.

Psychedelic therapies as a test of Europe’s preparedness

The brief presents psychedelic therapies as a test of Europe’s ability to turn science into patient access. These complex interventions raise questions about how the medicine, psychological support and treatment environment interact, and what must be standardised for safe and effective delivery.

PAREA proposes making psychedelic therapies an early test case for regulatory sandboxes, helping establish appropriate ways to assess the whole intervention and generate evidence for regulatory decisions and clinical practice.

The brief also calls for coordinated evidence generation through regulated national supervised-access programmes, with real-world evidence complementing clinical trials.

A call to action

Europe needs conditions that attract commercial investment and enable public institutions to advance treatments where market incentives are insufficient.

By securing mental health provisions in the Biotech Act and backing them with investment, clinical capacity and public-interest development, EU policymakers can help ensure that scientific progress translates into patient benefit.

Patients’ future access should not depend entirely on whether and when companies choose to enter the European market.

Read the full policy brief here.

Next
Next

PAREA and UPRA bring Ukraine’s research barriers to UN expert panel